J7172 (HCPCS) Reimbursement & Policy Benchmarks | OpenPayer

Summary & Overview

HCPCS J7172: Injection, marstacimab-hncq, 0.5 mg

HCPCS Level II code J7172 denotes the administration unit for marstacimab-hncq, a biologic injectable measured in 0.5 mg increments. Nationally, biologic drug codes like J7172 are critical for tracking utilization, standardizing billing across outpatient infusion settings, and supporting coverage determinations for specialty medications. Payers have varying coverage policies and prior authorization processes for high-cost biologics; this analysis focuses on major national plans including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of what J7172 represents clinically and operationally, followed by benchmarking elements and policy context. The publication summarizes typical sites of service and coding practice implications for outpatient infusion and clinic-based administration. Where available, it highlights payer coverage approaches, common billing modifiers used with injectable biologics, and relevance for service lines handling specialty drug administration. The content is designed to inform billing managers, revenue cycle professionals, and policy analysts about how this HCPCS Level II code functions in clinical billing workflows and payer interactions at a national level.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ7172HCPCS Level IImarstacimab-hncqbiologic injectioninfusion servicesoutpatient administrationspecialty pharmacymedical billingdrug unit code

Billing Code Overview

HCPCS Level II code J7172 represents Injection, marstacimab-hncq, 0.5 mg. This code is used to report administration of the specific biologic product marstacimab-hncq in 0.5 mg units. The service type is medication administration of a biologic injectable. The typical site of service for this administration is outpatient infusion or injection settings, including physician offices, outpatient infusion centers, and clinic-based administration.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with a rare bleeding or hematologic disorder enrolled in specialty infusion therapy who receives parenteral biologic therapy with marstacimab-hncq. The drug is supplied and billed as J7172 per 0.5 mg unit. The clinical workflow begins with a hematology or specialty pharmacy consult confirming indication and dosing. On the day of treatment the patient arrives at an outpatient infusion center, specialty clinic, or hospital outpatient department. Nursing completes pre-infusion assessment (vital signs, review of allergies, recent labs such as CBC and coagulation studies), verifies the marstacimab-hncq dose prepared by pharmacy, and documents consent and medication administration. The medication is administered via subcutaneous or intravenous route per product labeling and monitoring occurs for immediate hypersensitivity, infusion reactions, and hemodynamic changes. Post-administration nursing documents lot number, amount administered (units of J7172), site of administration, and any modifier(s) applicable for reporting. Billing uses J7172 units based on the actual milligrams administered divided by 0.5 mg per unit. Typical sites of service are outpatient infusion centers, physician offices (specialty clinics), and hospital outpatient departments. Common patient scenarios include repeat scheduled maintenance doses, loading-dose encounters, or on-study administrations in clinical research settings. Documentation includes diagnosis linking to the indication, medication administration record, and any applicable modifier to reflect unusual circumstances (e.g., bilateral procedure, reduced services, or discontinued infusion).

Coding Specifications

Modifier	Description

Related Codes

HCPCS-J2305-NITROGLYCERIN-INJECTION-5MG

HCPCS J2305: Injection, Nitroglycerin 5 mg

HCPCS-J3398-VORETIGENE-NEPARVOVEC-RZYL-1B-VECTOR-GENOMES

HCPCS J3398: Voretigene Neparvovec-Rzyl Injection, 1 Billion Vector Genomes

HCPCS-J2212-METHYLNALTREXONE-INJECTION-0-1-MG

HCPCS J2212: Methylnaltrexone Injection, 0.1 mg

HCPCS-J2460-OXYTETRACYCLINE-INJECTION-UP-TO-50-MG

HCPCS J2460: Injection, Oxytetracycline HCl, Up to 50 mg

HCPCS-J2515-PENTOBARBITAL-INJECTION-50MG

HCPCS J2515: Pentobarbital Sodium Injection, 50 mg

HCPCS-J1890-CEPHALOTHIN-INJECTION-1G

HCPCS J1890: Injection, Cephalothin Sodium, up to 1 Gram

HCPCS-J3358-USTEKINUMAB-INTRAVENOUS-1MG

HCPCS J3358: Ustekinumab for Intravenous Injection, 1 mg

HCPCS-J2725-PROTIRELIN-INJECTION-250-MCG

HCPCS J2725: Protirelin Injection, 250 mcg

HCPCS-J0692-CEFEPIME-500MG-INJECTION

HCPCS J0692: Injection, Cefepime Hydrochloride 500 mg

HCPCS-J7321-HYALURONAN-INTRA-ARTICULAR-INJECTION

HCPCS J7321: Hyaluronan Injection for Intra-articular Use

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology & Oncology	Hematologists/oncologists commonly prescribe and oversee marstacimab-hncq therapy.
`207L00000X`	Allergy & Immunology	Allergists/immunologists manage biologic therapies for immune-mediated bleeding disorders.
`177H00000X`	Nurse Practitioner	NPs frequently manage dosing, orders, and administration in infusion clinics.
`164W00000X`	Physician Assistant	PAs commonly support specialty clinics administering biologic infusions.
`3336S0205X`	Infusion Therapy Nurse	Specialized infusion nurses administer and monitor parenteral biologic therapies.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D68.4`	Acquired coagulation factor deficiency	Hemostatic disorders that may be treated with targeted biologic agents or require specialty therapy.
`D68.9`	Coagulation defect, unspecified	General coagulation abnormalities that can necessitate biologic or replacement therapies.
`D69.3`	Immune thrombocytopenic purpura	Autoimmune-mediated bleeding disorder where biologic agents may be part of specialty management.
`D66`	Hereditary factor VIII deficiency (Hemophilia A)	Severe congenital bleeding disorder; specialty biologic therapies may be used in management or trials.
`D67`	Hereditary factor IX deficiency (Hemophilia B)	Another hereditary bleeding disorder managed in specialty infusion settings.
`Z79.899`	Other long term (current) drug therapy	Used to indicate ongoing long-term biologic therapy maintenance dosing.
`Z51.81`	Encounter for therapeutic drug monitoring	Used when the visit includes monitoring or adjustment of biologic therapy.
`R79.9`	Abnormal finding of blood chemistry, unspecified	Used when abnormal labs prompt specialty biologic treatment or monitoring.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used when the `J7172` preparation is administered as an IV infusion and initial infusion time is up to 1 hour.
`96366`	Intravenous infusion, each additional hour	Used for extended infusion time beyond the initial hour when monitoring and infusion continue.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug) subcutaneous or intramuscular	Used when `J7172` is administered as a subcutaneous injection.
`36415`	Collection of venous blood by venipuncture	Used for pre-infusion lab draws such as CBC or coagulation studies required for safe administration.
`99070`	Supplies and materials (e.g., gloves, syringes)	Used to bill separately for non-covered supplies used during preparation and administration when allowed.

`00`	No modifier applicable (default)	Use when no additional reporting modifier is required for the `J7172` administration.
`22`	Increased procedural services	Use when administration required substantially greater work or time than typical (e.g., prolonged management of severe infusion reaction).
`23`	Unusual anesthesia	Use when unusual anesthesia unrelated to procedure is provided during the infusion visit (rare for `J7172`).
`52`	Reduced services	Use when the full planned administration is partially reduced but still billed (dose reduction documented).
`53`	Discontinued procedure	Use when the infusion is started but discontinued due to adverse reaction or patient intolerance.
`54`	Surgical care only	Not commonly used for drug administration; apply only if separate surgical component exists.
`55`	Postoperative management only	Not commonly used; apply only if postoperative care is billed separately from the drug.
`62`	Two surgeons	Rare for drug administration; use if two qualified providers are required for the encounter.
`78`	Unplanned return to OR	Not typically applicable; include only if adverse event required urgent operative intervention during the visit.
`80`	Assistant at surgery	Not applicable for routine drug administration; include only if surgical assistant services are involved.
`82`	Assistant not available	As above, only if an assistant was necessary and not available.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant	Use when applicable advanced practitioner performs part of the service under supervision.
`CQ`	Service furnished by a CRNA/AA under medical direction of a physician	Use when certified registered nurse anesthetist/anaesthesia assistant provided services during the encounter.
`TG`	Service provided using a registered dietitian or nutrition professional	Rare; apply only if nutrition professional services are separately billed during the visit.